Replimune Group (REPL) Stock Overview
A clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
REPL Community Fair Values
Create NarrativeSee what 13 others think this stock is worth. Follow their fair value or set your own to get alerts.
Replimune Group, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$8.80 |
| 52 Week High | US$17.00 |
| 52 Week Low | US$2.68 |
| Beta | 0.42 |
| 1 Month Change | 111.54% |
| 3 Month Change | 179.37% |
| 1 Year Change | -24.98% |
| 3 Year Change | -51.30% |
| 5 Year Change | -78.95% |
| Change since IPO | -41.95% |
Recent News & Updates
Recent updates
Replimune: Acceptance Confirms Completeness, Not Approval (Rating Upgrade)
Oct 21Is Replimune Group (NASDAQ:REPL) A Risky Investment?
Aug 01
Replimune: Scope Goes Beyond That Of RP1 Oncolytic Targeting For Melanoma
Apr 28Is Replimune Group (NASDAQ:REPL) A Risky Investment?
Apr 11Replimune: A Misunderstood Contender In Oncolytics
Feb 12Replimune: RPL1 BLA Submission Under AA Pathway Makes It A Must Watch
Nov 29Replimune Group (NASDAQ:REPL) Has Debt But No Earnings; Should You Worry?
Nov 23Replimune: Strong Data In A Highly Differentiated Space
Sep 03Is Replimune Group (NASDAQ:REPL) Using Debt Sensibly?
Aug 16Replimune: Continuing To Justify The Bear Thesis (For Now)
May 22Replimune Group (NASDAQ:REPL) Has Debt But No Earnings; Should You Worry?
Feb 06Replimune: The Fall Is Justified, As Virus Therapy Fails Again In Cancer
Jan 23Calculating The Intrinsic Value Of Replimune Group, Inc. (NASDAQ:REPL)
Dec 25Is Replimune Group (NASDAQ:REPL) A Risky Investment?
Jul 13Is Replimune Group (NASDAQ:REPL) Using Debt In A Risky Way?
Apr 05A Look At The Fair Value Of Replimune Group, Inc. (NASDAQ:REPL)
Jan 06Replimune secures $200M term loan
Oct 07Replimune: Recent Developments Strengthen Bull Thesis
Aug 12Replimune Group (NASDAQ:REPL) Has Debt But No Earnings; Should You Worry?
Aug 06Replimune Group GAAP EPS of -$0.78 misses by $0.15
Aug 04Replimune Group, Inc. (NASDAQ:REPL) Shares Could Be 23% Below Their Intrinsic Value Estimate
Jun 24We're Not Very Worried About Replimune Group's (NASDAQ:REPL) Cash Burn Rate
Apr 04Companies Like Replimune Group (NASDAQ:REPL) Are In A Position To Invest In Growth
Dec 16Shareholder Returns
| REPL | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 95.6% | -0.01% | 1.3% |
| 1Y | -25.0% | 2.0% | 16.7% |
Return vs Industry: REPL underperformed the US Biotechs industry which returned 2% over the past year.
Return vs Market: REPL underperformed the US Market which returned 16.7% over the past year.
Price Volatility
| REPL volatility | |
|---|---|
| REPL Average Weekly Movement | 44.0% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 17.3% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: REPL's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: REPL's weekly volatility has increased from 27% to 44% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 479 | Sush Patel | www.replimune.com |
Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer. The company’s proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF for a range of solid tumors.
Replimune Group, Inc. Fundamentals Summary
| REPL fundamental statistics | |
|---|---|
| Market cap | US$657.23m |
| Earnings (TTM) | -US$280.22m |
| Revenue (TTM) | n/a |
Is REPL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| REPL income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$280.22m |
| Earnings | -US$280.22m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.59 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 13.9% |
How did REPL perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/24 21:45 |
| End of Day Share Price | 2025/10/24 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2025/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Replimune Group, Inc. is covered by 14 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Peter Lawson | Barclays |
| Evan Seigerman | BMO Capital Markets Equity Research |
| Clarence Powell | BMO Capital Markets Equity Research |